Karen Lee, MD
Internal Medicine · Elmhurst, NYNPI 1629124045
Payments from drug & device makers
Across 353 payments — averaging $20.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Pfizer$843
- Gilead$826
- Amgen$793
- GSK$695
- Boehringer Ingelheim$481
- plus $2K from 14 others
What the payments were for
- Food & beverage$7,23799%
- Education$531%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 84 | $1,801 |
| Pfizer | 47 | $843 |
| Gilead | 34 | $826 |
| Amgen | 37 | $793 |
| GSK | 30 | $695 |
| Boehringer Ingelheim | 25 | $481 |
| Amarin Pharma, Inc. | 23 | $361 |
| Exact Sciences | 17 | $333 |
| Merck | 13 | $235 |
| Novo Nordisk | 12 | $225 |
| Lilly USA, LLC | 11 | $188 |
| Dexcom, Inc. | 1 | $142 |
| Sanofi Pasteur Inc. | 6 | $118 |
| AbbVie | 5 | $95 |
| E.r. Squibb & Sons, L.L.C. | 2 | $44 |
| Mannkind Corporation | 1 | $32 |
| Novartis | 2 | $29 |
| Abbott | 1 | $23 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G7 GSS (161)$142
- FARXIGA$125
How this compares
$7,290 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 198 | $179,093 |
| FarxigaDapagliflozin Propanediol | 160 | $173,479 |
| VascepaIcosapent Ethyl | 484 | $142,825 |
| OzempicSemaglutide | 73 | $93,839 |
| MounjaroTirzepatide | 51 | $72,216 |
| EliquisApixaban | 71 | $70,554 |
| TrulicityDulaglutide | 45 | $48,199 |
| Diclofenac Epolamine | 57 | $38,748 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $38,561 |
| JanumetSitagliptin Phos/Metformin Hcl | 44 | $34,960 |
| JanuviaSitagliptin Phosphate | 28 | $33,183 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 53 | $32,520 |
| VemlidyTenofovir Alafenamide | 21 | $29,712 |
| XareltoRivaroxaban | 26 | $29,449 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 88 | $29,214 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Trijardy Xr, Synjardy, Glyxambi, Combivent Respimat | $481 | $228,822281 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,801 | $205,999213 claims |
| Lilly USA, LLCMounjaro, Trulicity | $188 | $120,41596 claims |
| Novo NordiskOzempic | $225 | $93,83973 claims |
| PfizerEliquis | $843 | $70,55471 claims |
| MerckJanumet, Januvia | $235 | $68,14372 claims |
| AbbVieLinzess, Restasis, Synthroid | $95 | $47,678131 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $695 | $43,67052 claims |
| GileadVemlidy | $826 | $29,71221 claims |
| Johnson & JohnsonXarelto | $11 | $29,44926 claims |
| AmgenProlia | $793 | $25,21515 claims |
| NovartisEntresto | $29 | $18,47318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Elmhurst
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.